ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

CD137/Nectin-4 Bispecific-targeting Agent BT7480

Its studies are led by BicycleTx.

Furthest: phase 2, since Nov 19, 20212 company-led studies, 2 open or runningNext primary completion: May 30, 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BicycleTx22 open or runningphase 2since Nov 19, 2021Nov 19, 2021May 30, 2030phase 2 · NCT07681674

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 19, 2021First study: phase 2 study in Advanced Solid TumorFirst studyNCT05163041 · 200 enrolled · United States, United Kingdom
  2. Jun 26, 2026Phase 2 study in Advanced Solid TumorsNCT07681674 · 16 planned

Ahead

  1. May 30, 2030Primary completion: phase 2 study in Advanced Solid TumorsNCT07681674

TargetBeta

TNFRSF9 →read by rule
“A synthetic tumor targeted immune cell agonist composed of two bicyclic peptides targeting CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9) ”NCIt, by rule

Other programs on TNFRSF9

ProgramCompanyFurthest phaseStudies
Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rulenanjing-leads-biolabs-co-ltdphase 310
acasunlimabruleGenmabphase 36
Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033ruleBeOne Medicinesphase 33
Anti-CD137 Agonistic Monoclonal Antibody CTX-471rulecompass-therapeuticsphase 22
Anti-EpCAM/Anti-4-1BB Bispecific Antibody BNT314ruleBioNTechphase 22
Anti-B7-H4/Anti-4-1BB Bispecific Antibody ABL103ruleabl-bio-incphase 22
Anti-CEA/Anti-4-1BB Bispecific Antibody LM-24C5Sino Biopharmaceuticalphase 22
Anti-PSMA/Anti-4-1BB Bispecific Antibody REGN15505ruleRegeneron Pharmaceuticalsphase 21
LM-2417Sino Biopharmaceuticalphase 21
clesitamigHoffmann-La Rochephase 12
Anti-CD137/PD-L1 Bispecific Antibody FS222Sino Biopharmaceuticalphase 11
Autologous NY-ESO-1/LAGE-1a-specific HLA-A*02:01-restricted TCR-expressing T-lymphocytes MDG1015rulemedigene-agphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07681674Advanced Solid Tumors2Not yet recruitingMay 30, 203016
NCT05163041Advanced Solid Tumor · United States, United Kingdom2Active, not recruitingAug 2026200

How it is read

Names in the registry

  • “BT7480”, 2 entries

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.